reeclampsia is a major complication in pregnancy that increases maternal and fetal morbidity and mortality. 1, 2 Placental hypoxia, caused by impaired uterine spiral artery remodeling and reduced uteroplacental blood flow, plays a central role in the pathophysiology of preeclampsia, which includes chronic inflammation, endothelial dysfunction, hypertension, tissue ischemia, and proteinuria. [1] [2] [3] [4] [5] [6] Pregnancy is often accompanied by a mild hypercoagulable state, 7-12 which may be evolved to prevent excessive bleedings at childbirth. In preeclampsia, enhanced blood coagulation is more substantial, which increases the thrombotic risk. 1, 7, 10, 11 Despite the clinical importance, the mechanisms underlying preeclampsia-associated thrombophilia are not fully understood.
HMGB1 (high-mobility group box 1) is a proinflammatory protein. 24, 25 It causes endothelial dysfunction 26, 27 and promotes leukocyte activation and thrombosis. [28] [29] [30] Increased HMGB1 expression has been reported in the placenta or placental explant-derived extracellular vesicles from patients with preeclampsia . [31] [32] [33] [34] High levels of receptor for advanced glycation end-products, an HMGB1 receptor, were also found in preeclampsia sera. 35 In culture, trophoblast-derived HMGB1 increased endothelial cell permeability in a TRL4 (Toll-like receptor 4)-and caveolin-1-dependent mechanism. 36 These data suggest a potential role of HMGB1 in preeclampsia.
In this study, we sought to understand the mechanism connecting placental hypoxia, maternal endothelial dysfunction, and increased thrombotic risk in preeclampsia. We examined plasma microparticles in preeclampsia women, analyzed human trophoblasts under normoxia and hypoxia, did proteomic analysis of trophoblast-secreted proteins, conducted experiments in pregnant mice, and tested placental tissues from preeclampsia women. Our results indicate that increased HMGB1 expression and release from hypoxic trophoblasts play an important role in causing maternal endothelial damage and producing endothelial cell-derived microparticles that promote blood coagulation in preeclampsia.
Materials and Methods

Human Plasma and Tissue Samples
Human blood and placental samples were collected at the Second Affiliated Hospital of Soochow University. The study was approved by the ethics committee of the university and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. Participant characteristics are shown in Table I in the online-only Data Supplement. Preeclampsia was diagnosed by new-onset high blood pressure (≥140/90 mm Hg) and proteinuria (≥300 mg/24 h) at ≥20 weeks of gestation. 1 Blood coagulation tests were done at the hospital laboratory. Venous blood samples were drawn into tubes with sodium citrate (3.2%) in a 9:1 (v/v) ratio and centrifuged at 1500g for 10 minutes to obtain plasma, which was centrifuged subsequently at 13 000g for 2 minutes. The platelet-free plasma was collected and stored at −80°C until use. For preeclampsia women, blood samples were taken before treatment. All participants for placental studies delivered by primary C-section without labor. Placentae were collected immediately after the delivery. Biopsies from the placental center and each quadrant were taken, snap frozen in liquid nitrogen, and stored at −80°C.
Analysis of Microparticles in Human Plasma
Microparticles were analyzed by flow cytometry 37 with fluorescein isothiocyanate-, phycoerythrin-, or peridinin-chlorophyll-protein complex-conjugated antibodies. Plasma (50 µL) was diluted with PBS (50 µL) and incubated with an fluorescein isothiocyanate-conjugated anti-annexin V antibody (BD Biosciences, 556547) for total microparticles or conjugated-antibodies against platelets (CD41a-fluorescein isothiocyanate, 555467), leukocytes (CD45-peridinin-chlorophyllprotein complex, 347464), red blood cells (CD235a-phycoerythrin, 340947), endothelial cells (CD31-phycoerythrin, 555448 or CD62e-phycoerythrin, 551145; all from BD Biosciences), tissue factor (Bioss, bs-4690R-PE), or an antiplacental alkaline phosphatase antibody (Abcam, ab33) and a phycoerythrin-conjugate secondary antibody (BD Biosciences, 550589). Reference beads (5 µL) of known concentrations (Flow-Count Fluorospheres; Beckman Coulter, 7547053) were included. Conjugated and isotype-matched control antibodies (IgG1-fluorescein isothiocyanate, 551954; IgG1-phycoerythrin, 555749; IgG1-peridinin-chlorophyll-protein complex, 559425, BD Biosciences) were used as negative controls. Data were acquired and analyzed with a flow cytometer (Cytomics FC 500; Beckman Coulter).
Human Trophoblast Culture
Human JEG-3 trophoblasts (ATCC [American Type Culture Collection]) and primary human villous trophoblasts (HVT) (ScienCell Research Labs) were cultured as described previously. 3 Normoxic or hypotonic hypoxia experiments were done with 20% or 1% O 2 .
Histogenous hypoxia experiments were done with rotenone (0.5 μmol/L, TCI Development, China), which disrupts the mitochondrial electron transport chain. 38 After 6 hours, the medium was replaced with opti-MEM without rotenone for 24 hours. To isolate microparticles, the conditioned medium was centrifuged at 1500g for 15 minutes to remove cell debris. The supernatant was centrifuged at 20 000g, 4°C for 40 minutes. Pelleted microparticles were washed and resuspended in RPMI (Roswell Park Memorial Institute) 1640 medium (Hyclone). The microparticles-free supernatant was fractionated with centrifugal filters of different molecular weight cutoffs (Millipore).
Analysis of Microparticles From HUVECs
Human umbilical vein endothelial cells (HUVECs; ATCC) were cultured with RPMI 1640 medium and 10% fetal bovine serum in 6-well plates and treated with 1.5 mL of the conditioned medium, microparticle-free conditioned medium or microparticles (2×10 6 /mL) from JEG-3 cells, or 100 ng/ mL of tumor necrosis factor-α (PeproTech) or human recombinant HMGB1 (rHMGB1; Sino Biological, China). After 24 hours, the medium was collected, and HUVEC-derived microparticles were analyzed, as described above. To deplete HMGB1 from the trophoblast medium, an anti-HMGB1 antibody (10 µg; Abcam, ab18256) or control IgG (10 µg) was incubated with the conditioned medium (2 mL) from hypoxic JEG-3 cells at 4°C for 4 hours followed by immunoprecipitation to remove the antibody-HMGB1 complex. 39 The supernatant (1.5 mL) was added to HUVECs to test the effect on microparticle production. To inhibit HMGB1 in the hypoxic JEG-3 medium, HMGB1 box A fragment (2 µg/mL; HMGBiotech, Italy) or glycyrrhizin (200 µg/mL; Sigma) was added to the conditioned medium and incubated with HUVECs for 24 hours. Endothelial microparticles in the medium were examined by flow cytometry.
Proteomic Analysis
The conditioned medium from JEG-3 cells cultured without (normal) or with rotenone (hypoxic) was concentrated ≈20-fold using Amicon filters (Millipore) with 3-, 50-, and 100-kDa molecular weight cutoffs. Proteomic analysis of the isolated proteins was done by in-solution trypsin digestion and liquid chromatography-mass spectrometry analysis at Shanghai Applied Protein Technology (China). Identified peptide sequences in the hypoxic, but not normoxic, conditioned medium were searched against the Uniprot database using Mascot 2.2 software.
Analysis of HMGB1 mRNA Expression
Total RNAs from cultured trophoblasts or placental tissues were used to make cDNA templates with a reverse transcription kit (Thermo Scientific). HMGB1 mRNA expression was analyzed by quantitative reverse transcription polymerase chain reaction (ABI 7500) with primers 5′-TCA AAG GAG AAC ATC CTG GCC TGT-3′ and 5′-CTG CTT GTC ATC TGC AGC AGC AGT GTT-3′. Primers for β-actin were included as a control. 
HMGB1 Immunostaining
Western Blotting
To analyze HMGB1 protein, JEG-3 and HVT cell lysates and human placental homogenates were prepared. 41 Proteins (10 µg per sample) were analyzed by SDS-PAGE and Western blotting with an anti-HMGB1 (Abcam, ab79823, 0.0152 μg/mL) or anti-GAPDH (GenScript, Ad00192, 0.05 μg/mL) antibody and a horseradish peroxidase-conjugated secondary antibody (Bioworld, BS13278, 0.2 μg/mL). The blot was developed using enhanced chemiluminescent reagents. Immunoreactive bands were quantified using Image J software and normalized with GAPDH values in the same lane.
Apoptosis in JEG-3 and HVT Cells
Apoptosis in normoxic and hypoxic JEG-3 and HVT cells was analyzed by flow cytometry using an annexin V-PE/7-AAD (phycoerythrin/7-amino-actinomycin) apoptosis kit (LianKeBio, China). The cells were detached by trypsin digestion, washed with PBS, and labeled with annexin V-phycoerythrin and 7-AAD at 4°C for 30 minutes. The cells were analyzed by flow cytometry.
HMGB1 ELISA
HMGB1 levels in the conditioned media from normoxic and hypoxic JEG-3 and HVT cells and in human plasma were measured by ELISA (Shino-test, Japan), according to the manufacturer's instructions.
Electron Microscopy
Microparticles from rHMGB1-stimulated HUVECs were fixed with 2.5% glutaraldehyde (Ourchem, China) in 0.1 mol/L PBS, pH 7.4, at 4°C for 4 hours, deposited on the carbon-coated grid, and treated with 2% phosphotungstic acid (Sigma). Images were taken with a transmission electron microscopy (Tecnai G220, TEI).
HUVEC Permeability
The permeability of rHMGB1-treated HUVECs was examined by flow cytometry. The cells were washed with PBS and incubated with propidium iodide at room temperature for 10 minutes, followed by flow cytometric analysis of propidium iodide-staining cell.
Thrombin Generation Assay
In a fluorimetric assay, 42 increasing numbers of HUVEC-derived microparticles were added to human plasma. A thrombin fluorogenic substrate (Z-Gly-Gly-Arg-AMC) and CaCl 2 (25 mmol/L) were added 
DNA Released From Neutrophils
Human neutrophils were isolated from peripheral blood by dextran sedimentation and Percoll II (Amersham Biosciences) gradient methods. 43 Neutrophils (1×10 5 /well) were added to 96-well plates and incubated with HUVEC-derived microparticles (2×10 6 /mL) or control buffer at 37°C. After 4 hours, released DNA in the supernatant was measured by Quant-iT PicoGreen dsDNA reagents (Invitrogen).
Effects of rHMGB1 in Mice
The study was approved by the Animal Care and Use Committee of Soochow University, and the experiments were conducted in accordance with the approved protocol. Two-month-old male and female C57BL/6 mice were kept at a specific pathogen-free facility under 12/12-hour light/dark cycles with free access to chow diet and water. Mated female mice were checked for vaginal plugs to establish gestation timing. The day on which a plug was detected was defined as day 0.5 post-coitum. On day 18.5 post-coitum, pregnant or agematched control nonpregnant female mice (n=8 per group) were held transiently in a restrainer and injected with rHMGB1 (50 µg in 200 µL saline) or saline control via tail vein. After 1.5 hours, the mice were euthanized, and blood was collected via vena cava. Total and endothelial microparticles in plasma, blood coagulation, and plasma DNA levels were analyzed.
Statistical Analysis
Analysis was done using SPSS 17.0 and Prism 7 software. Equal variance and normality of the data were verified by Levene test and Kolmogorov-Smirnov test, respectively. If the data passed the normality and equal variance tests, Student t test was used to compare 2 groups or 1-way ANOVA followed by Bartlett test for comparisons among ≥3 groups. If the data did not pass the normality or equal variance test, Mann-Whitney test was used for 2 independent sample comparisons, and Kruskal-Wallis test and Mann-Whitney test with Bonferroni correction were used for multiple comparisons. Correlations were analyzed with the Pearson method. Data are presented as mean±SEM. P<0.05 is considered to be statistically significant.
Results
Plasma Microparticles in Preeclampsia Women
By flow cytometry, we found high levels of plasma microparticles in PE women compared with those in nonpregnant and normal pregnant women ( Figure 1A ). By analyzing protein Figure 1B) . Levels of trophoblast-derived microparticles also increased in preeclampsia woman but were ≈6-fold less than that of endothelial microparticles. In contrast, levels of platelet-, red blood cell-, and leukocytederived microparticles were similar in normal pregnant and preeclampsia women ( Figure 1B) .
Preeclampsia is associated with enhanced blood coagulation. We found shortened activated partial thromboplastin time and prothrombin time, high levels of fibrinogen D-dimer, and low levels of antithrombin III in preeclampsia women compared with those in normal pregnant women ( Figure I in the online-only Data Supplement). In those individuals, plasma endothelial microparticle levels correlated with prothrombin time, plasma D-dimer, and antithrombin III levels ( Figure 1C  and 1D ), whereas no correlation was found between endothelial microparticle levels and activated partial thromboplastin time ( Figure II in the online-only Data Supplement).
Endothelial Microparticle-Stimulating Activity From Trophoblasts
Placental hypoxia plays a key role in preeclampsia. High levels of plasma endothelial microparticles in preeclampsia women suggest that hypoxia may induce trophoblasts to secrete factor(s) to cause maternal endothelial damage and release of microparticles. We cultured JEG-3 trophoblasts under normoxic and hypoxic conditions and tested the conditioned medium for microparticle-stimulating activity in HUVECs. We detected an increased microparticle-stimulating activity in the conditioned medium from hypoxic, but not normoxic, JEG-3 cells (Figure 2A) .
To exclude the possibility that the activity was from hypoxic JEG-3 cell-derived microparticles, we isolated microparticles from hypoxic JEG-3 cells and tested the microparticles and microparticle-free medium for the microparticle-stimulating activity in HUVECs. We found that the activity was associated with the microparticle-free hypoxic conditioned medium but not JEG-3 cell-derived microparticles ( Figure 2B ), indicating that secreted factor(s) from hypoxic JEG-3 cells stimulated endothelial microparticles in our experiments.
To identify such factor(s), we fractionated the hypoxic JEG-3 cell-conditioned medium based on molecular masses and assayed for the microparticle-stimulating activity in HUVECs. The activity was found in the 3-to 50-kDa fraction ( Figure 2C ), indicating that the microparticle-stimulating activity in the conditioned medium was from protein(s) of 3 to 50 kDa.
Identification of HMGB1 by Proteomic Analysis
We prepared the conditioned medium from normoxic and hypoxic JEG-3 cells and did proteomic analysis to identify differentially expressed proteins. A total of 238 proteins were found in the conditioned medium from hypoxic, but not normoxic, JEG-3 cells, of which 42 were of >100 kDa, 80 were of 50 to 100 kDa, and 116 were of 5 to 50 kDa (Table II in Among the 5-to 50-kDa fraction, HMGB1, a 25-kDa protein, appeared a candidate. When HMGB1 was immune depleted from the hypoxic JEG-3 cell medium, the endothelial microparticle-stimulating activity was reduced ( Figure 3A) . Moreover, when the hypoxic JEG-3 medium was treated with known HMGB1 inhibitors, HMGB1-derived box A fragment 44 and the natural compound glycyrrhizin, 45 the endothelial microparticle-stimulating activity was abolished ( Figure 3B ), indicating that HMGB1 was a primary factor from the hypoxic JEG-3 cells for stimulating endothelial microparticle production.
HMGB1 Expression and Release in Hypoxic Trophoblasts
We examined HMGB1 expression in JEG-3 cells under normoxia (20% O 2 ) and hypoxia (1% O 2 ). To ensure that findings reflect those of trophoblasts but not a particular cell line, we did similar experiments in primary HVTs. An ≈4-fold increase in HMGB1 mRNA expression was found in hypoxic JEG-3 and HVT cells ( Figure 4A ). Similar results were found when the cells were treated with rotenone that caused histogenous hypoxia ( Figure 4B ). In Western blotting, HMGB1 protein levels were increased in hypoxic JEG-3 and HVT cells, compared with those in normoxic cells ( Figure 4C and 4D) . Immunostaining showed increased HMGB1 in hypoxic JEG-3 and HVT cell nuclei ( Figure 4E and 4F) . In flow cytometry, more apoptotic JEG-3 and HVT cells were found under hypotonic or histogenous hypoxia ( Figure 4G and 4H) . ELISA also detected high HMGB1 levels in the hypoxic JEG-3 and HVT cell-conditioned media ( Figure 4I and 4J) . These results show that HMGB1 expression and release were increased in hypoxic trophoblasts in culture.
Effects of rHMGB1 on HUVECs
We treated HUVECs with purified human rHMGB1 and detected increased microparticles in the conditioned medium . In parallel, the CM from hypoxic trophoblasts was incubated with an anti-HMGB1 antibody (Hmgb1 Ab) or a control IgG before being added to HUVECs. Endothelial MP production was analyzed by flow cytometry. B, In similar experiments, the CM from hypoxic trophoblasts was incubated with HMGB1-derived box A fragment (HMGB1 box A) fragment (2 µg/mL) or glycyrrhizin (GL; 200 µg/ mL) before being added to HUVECs. Endothelial MP production was analyzed by flow cytometry. n=6 per group; Data were analyzed by 1-way ANOVA and presented as mean±SEM.
( Figure 5A ). In electron microscopy, the microparticles from rHMGB1-stimulated HUVECs were ≈150 to 200 nm in diameter ( Figure 5B), consistent with the size of microparticles. 14, 15 In flow cytometry, more propidium iodide-positive cells were found in rHMGB1-treated HUVECs ( Figure 5C ). These results indicate that rHMGB1 damaged HUVECs and increased the cell permeability and microparticle production.
rHMGB1-Stimulated Endothelial Microparticles Enhance Blood Coagulation and Neutrophil Activation
We examined the effect of rHMGB1-stimulated endothelial microparticles on blood coagulation. 42 The microparticles from rHMGB1-stimulated HUVECs increased thrombin generation peaks and shortened peak formation times ( Figure 5D and 5E). When the rHMGB1-stimulated endothelial microparticles were incubated with isolated human neutrophils, higher levels of extracellular DNA were detected in the medium ( Figure 5F ), indicating that the endothelial microparticles activated the neutrophils, inducing DNA release.
rHMGB1 Increases Circulating Endothelial Microparticles, Blood Coagulation, and Plasma DNA Levels in Pregnant Mice
To test the effect of HMGB1 in vivo, we intravenously injected rHMGB1 in pregnant and nonpregnant C57BL/6 mice. Compared with the saline control, rHMGB1 injection increased plasma total microparticles and endothelial Figure 6A and 6B) , shortened activated partial thromboplastin time and prothrombin time ( Figure 6C and 6D), and increased plasma DNA levels ( Figure 6E ) in pregnant, but not nonpregnant ( Figure 6F-6J) , mice, indicating that rHMGB1 injection increased endothelial microparticle production and enhanced blood coagulation and neutrophil activation in pregnant, but not nonpregnant, mice.
microparticles (
Placental and Plasma HMGB1 Levels in Normal Pregnant and Preeclampsia Women
We found an ≈2-fold increase of placental HMGB1 mRNA ( Figure 7A ) and protein ( Figure 7B and 7C) levels in preeclampsia women compared with those in normal pregnant women. ELISA showed higher plasma HMGB1 levels in preeclampsia women than those in nonpregnant and normal pregnant women ( Figure 7D ). There was a positive correlation between plasma HMGB1 and endothelial microparticle levels in nonpregnant, normal pregnant, and preeclampsia women ( Figure 7E ). These results support the idea that placental hypoxia-induced HMGB1 expression and release from trophoblasts are an important mechanism in maternal endothelial damage and microparticle production, which enhances blood coagulation and leukocyte activation in preeclampsia ( Figure 7F ).
Discussion
Preeclampsia is associated with high levels of circulating microparticles, 14, [16] [17] [18] [19] which may come from endothelial cells, platelets, leukocytes, and trophoblasts. In this study, we found that the increased plasma microparticles in preeclampsia women were mostly of endothelial origin. Unlike in other thrombotic disorders, 46, 47 platelet-derived microparticles were not increased in PE women. Trophoblast-derived microparticles were also higher in preeclampsia women, but the levels were ≈6-fold less than that of endothelial microparticles. Trophoblasts are a major cell type in the placenta. Our results indicate that the increased endothelial microparticles are likely of maternal, but not placental, origin. Microparticles are procoagulant. [13] [14] [15] In our study, circulating endothelial microparticle levels correlated with shortened prothrombin time, increased plasma fibrinogen D-dimer, and decreased antithrombin III levels in preeclampsia women. We also found that preeclampsia women had high levels of tissue factor-positive microparticles ( Figure III in the online-only Data Supplement). These results are consistent with endothelial damage and enhanced blood coagulation in preeclampsia. 11, 48, 49 Placental hypoxia plays a key role in preeclampsia. 1, 2, [4] [5] [6] Using an unbiased proteomic approach, we identified HMGB1 as a primary protein in the hypoxic trophoblast conditioned medium that stimulated HUVEC microparticles. This conclusion was supported by multiple lines of evidence. First, immunodepletion of HMGB1 from the hypoxic trophoblast medium inhibited the endothelial microparticle-stimulating activity. Second, incubation of HMGB1-derived box A fragment, an N-terminal HMGB1 fragment that antagonizes HMGB1 activity, 44, 50 abolished the endothelial microparticlestimulating activity from hypoxic trophoblasts. Third, a similar inhibitory effect was observed with glycyrrhizin, a natural compound that binds to and inhibits HMGB1. 45, 50 Moreover, purified rHMGB1 stimulated microparticle production in HUVECs and the microparticles from rHMGB1-stimulated HUVECs enhanced thrombin generation and induced neutrophil activation in vitro. These results indicate that HMGB1 from hypoxic trophoblasts is an important contributing factor in maternal endothelial damage and microparticle production, which in turn promotes blood coagulation and neutrophil activation in preeclampsia.
Oxidative stress and hypoxia are triggers for HMGB1 expression and release. [51] [52] [53] We found upregulated HMGB1 mRNA and protein expression in human trophoblasts cultured under hypotonic or histogenous hypoxia. We also detected increased apoptosis and HMGB1 release in similarly treated trophoblasts, indicating that HMGB1 upregulation and release are part of stress responses in hypoxic trophoblasts. Consistently, we found high levels of HMGB1 mRNA and protein in placentae from preeclampsia women. Moreover, elevated plasma HMGB1 levels correlated with increased plasma endothelial microparticles in these individuals. Our results are in agreement with previous reports of HMGB1 upregulation in hypoxic trophoblasts in culture and high HMGB1 expression in placentae and sera from preeclampsia women. [31] [32] [33] [34] 36, 54 HMGB1 is expressed in many cell types. Our findings of upregulated HMGB1 expression in trophoblasts do not exclude the possibility that other cells may also contribute to the elevated plasma HMGB1 in preeclampsia.
Placental hypoxia elicits a variety of cellular and inflammatory responses in preeclampsia, elevating circulating levels of many proinflammatory factors. 54 Is increased HMGB1 sufficient for promoting maternal endothelial microparticle production, blood coagulation, and neutrophil activation in pregnancy? In rHMGB1-injected pregnant mice, we observed increased plasma endothelial microparticles and blood coagulation. We also detected increased plasma DNA levels, indicating neutrophil activation and NETosis (neutrophil extracellular trap release) in vivo. These results show that elevated circulating HMGB1 is sufficient to promote maternal endothelial microparticle production and hypercoagulability in pregnant mice. Interestingly, similar rHMGB1 injection in nonpregnant female mice did not significantly alter plasma endothelial microparticle levels, blood clotting times, and plasma DNA levels, indicating that endothelial cells in nonpregnant mice are less sensitive to HMGB1 stimulation and that rHMGB1, at the dose tested, is insufficient to directly enhance blood coagulation and neutrophil activation in nonpregnant mice. Possibly, endothelial cells undergo phenotypic changes during pregnancy and become more susceptible to HMGB1-mediated damage. Alternatively, additional factor(s) from the pregnant uterus or the placenta act synergistically with HMGB1 to stimulate endothelial microparticle production. Further studies to examine the different HMGB1 responses in nonpregnant and pregnant mice will be important for understanding the role of HMGB1 in the pathophysiology of preeclampsia.
In summary, thrombophilia is a major complication in preeclampsia, a disease associated with placental hypoxia and trophoblast inflammation. In this study, we examined molecular mechanisms connecting placental hypoxia and thrombophilia in preeclampsia. Our results indicate that increased HMGB1 expression and release from hypoxic trophoblasts play an important role in promoting endothelial microparticle production, blood coagulation, and neutrophil activation, thereby contributing to thrombophilia. It should be pointed out that preeclampsia is a multifactorial disease. Many factors are expected to contribute to the preeclampsia-associated phenotype. Our findings should encourage more studies to define the role of HMGB1 in preeclampsia-related hypercoagulability and to test whether HMGB1 inhibition could be a therapeutic approach to reduce the thrombotic risk in preeclampsia. . Placental HMGB1 (high-mobility group box 1) expression and plasma HMGB1 levels in normal pregnant and preeclampsia (PE) women. A, Reverse transcription polymerase chain reaction analysis of placental HMGB1 mRNA expression in normal pregnant (NP) and PE women. Data (fold-change vs NP) were analyzed by Student t test. B and C, Western blotting of placental HMGB1 protein in NP and PE women. Data were normalized to GAPDH levels. Quantitative data in C were analyzed by Student t test. D, ELISA analysis of plasma HMGB1 levels in nonpregnant (Non-P), NP, and PE women. Data were analyzed by Kruskal-Wallis test and Mann-Whitney test with Bonferroni correction. E, Correlation between plasma HMGB1 and endothelial microparticle (EMP) levels in Non-P, NP, and PE women, as analyzed by the Pearson method. F, Proposed role of HMGB1 from hypoxic trophoblasts in causing maternal endothelial damage, producing endothelial MPs, and promoting blood coagulation and leukocyte activation in PE.
